Drugs for Glaucoma, Primary Open Angle (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 153)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Timolol |
Approved |
Phase 4 |
|
26839-75-8 |
5478 33624 |
Synonyms:
(-)-S-TIMOLOL
(S)-1-(TERT-BUTYLAMINO)-3-[(4-MORPHOLIN-4-YL-1,2,5-THIADIAZOL-3-YL)OXY]PROPAN-2-OL
Apo-Timol
Apo-Timop
Aquanil
BETIM
BETIMOL
BLOCADREN
GLAUCOL
GLAU-OPT
ISTALOL
Novo-Timol
Nu-Timolol
NYO142
NYOGEL
Phoxal-timolol
Proflax
Temserin
Tenopt
|
Timacar
Timacor
Tim-AK
TIMOLOL
TIMOLOL ANHYDROUS
TIMOLOL HEMIHYDRATE
Timolol maleate
Timololo
Timololum
Timololum [INN-Latin]
Timopic
TIMOPTIC
Timoptic in Ocudose
Timoptic OcuDose
Timoptic®
TIMOPTIC-XE
Timoptol
TIOPEX
|
|
2 |
|
Brinzolamide |
Approved |
Phase 4 |
|
138890-62-7 |
68844 |
Synonyms:
(R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
AL-4862
AL-4862|Azopt®
Alcon brand OF brinzolamide
|
Allphar brand OF brinzolamide
Azopt
Brinzolamida
BRINZOLAMIDE
|
|
3 |
|
Mitomycin |
Approved |
Phase 4 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
4 |
|
Latanoprost |
Approved, Investigational |
Phase 4 |
|
130209-82-4 |
5311221 5282380 |
Synonyms:
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoic acid
Latanoprost
Latanoprostum
MONOPOST
Pfizer brand OF latanoprost
PhXA 41
PhXA34
PHXA41
PHXA-41
|
PHXA-41|XA-41|Xalatan®
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoic acid
T2345
T-2345
XA-41
Xalatan
Xalatan Fixed Flow Device
XELPROS
|
|
5 |
|
Bimatoprost |
Approved, Investigational |
Phase 4 |
|
155206-00-1 |
5311027 |
Synonyms:
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
AGN 192024
AGN 192024|LS-181817|Lumigan®
AGN-192024
BIMATOPROST
|
Bimatoprostum
Latisse
LS-181817
Lumigan
|
|
6 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 4 |
|
1177-87-3 |
3680 |
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
2-{1-fluoro-14,17-dihydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethyl acetic acid
9alpha-Fluoro-16alpha-methylprednisolone acetate
DECADRON-LA
Dexamethasone 21-acetate
|
DEXAMETHASONE ACETATE
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasone acetic acid
Dexamethasoni acetas
|
|
7 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 4 |
|
50-02-2 |
3003 5743 |
Synonyms:
[<sup>3</sup>H]-dexamethasone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16Α-methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16a-methyl-9a-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
9a-Fluoro-16a-methylprednisolone
9a-Fluoro-16BETA-methylprednisolone
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-Fluoro-16alpha-methyl-prednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9Α-fluoro-16α-methylprednisolone
Adexone
Aeroseb-D
Aeroseb-dex
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
alpha -Fluoro-16-alpha -methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Bisu DS
Calonat
Corson
Corsone
Cortisumman
DALALONE
Decacort
Decacortin
Decaderm
Decadron
Decadron Tablets, Elixir
Decadron®|desametasone|fluormethylprednisolone
DECADRON-75
DECADRON-LA
Decagel
Decaject
Decaject l.a.
Decaject-l.a.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
DEX
DEXA
Dexa mamallet
DEXACEN-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexacortin
Dexa-cortisyl
DEXACORTISYL
Dexadeltone
Dexafarma
DEXAFREE
DEXAIR
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
DEXAMETHASONE
Dexaméthasone
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
DEXAMETHASONE METASULFOBENZOATE SODIUM
DEXAMETHASONE PALMITATE
Dexamethasone sodium phosphate
|
DEXAMETHASONE VALERATE
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dexinolon
Dexinoral
Dexone
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
Dexonium
Dexpak
DEXSOL
Dextelan
DEXTENZA
DEXYCU KIT
Dezone
Dinormon
DROPODEX
DXM
DXM833
DXMS
ECR brand OF dexamethasone
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Gammacorten
GPPE EAR SPY
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Tablets
HL-Dex
ICN brand OF dexamethasone
IontoDex
Isopto-dex
ISV-305
KORTICO INJECTION
Lokalison F
Loverine
Luxazone
MARTAPAN
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merz brand 1 OF dexamethasone
Merz brand 2 OF dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
Mymethasone
Naquasone (veterinary)
NEODECADRON
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC-34521
Ocu-trol
Oradexon
OTO-104
OTOMIZE
OZURDEX
Pet derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
Sandoz dexamethasone
SK-Dexamethasone
SOFRADEX
SPERSADEX COMP
Spoloven
Sunia sol D
Superprednol
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
Visumetazone
|
|
8 |
|
Cefuroxime |
Approved |
Phase 4 |
|
55268-75-2 |
5479529 |
Synonyms:
(6R,7R)-3-[(Carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-3-[(Carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
640/359
ANAPTIVAN
CEFTIN
Cefuroxim
Cefuroxima
CEFUROXIME
CEFUROXIMINE
Cefuroximo
|
Cefuroximum
Cephuroxime
CXM
KEFUROS
KEFUROX
Ketocef
Sharox
XIMOS
Zinacef
Zinacef danmark
|
|
9 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
10 |
|
Tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
11 |
|
Travoprost |
Approved |
Phase 4 |
|
157283-68-6 |
5282226 |
Synonyms:
(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
AL-6221
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
|
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
IZBA
Travatan
Travatan Z
TRAVOPROST
Travoprostum
Z, Travatan
|
|
12 |
|
Dorzolamide |
Approved |
Phase 4 |
|
120279-96-1 |
5284549 |
Synonyms:
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide
(4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulphonamide 7,7-dioxide
(4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
(4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulphonamide-7,7-dioxide
4-Ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonate amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
|
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonate amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonic acid amide
4S,6S-Dorzolamide
5,6-Dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
DORZANT
DORZOLAMID
DORZOLAMIDA
DORZOLAMIDE
Dorzolamide chibret
Dorzolamide hydrochloride
Dorzolamide, (trans)-isomer
DORZOLAMIDUM
MK-507
Trusopt
Trusopt®
|
|
13 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
14 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
15 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
16 |
|
Benzalkonium Compounds |
|
Phase 4 |
|
|
|
17 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
18 |
|
Anti-Infective Agents, Local |
|
Phase 4 |
|
|
|
19 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
20 |
|
Hormones |
|
Phase 4 |
|
|
|
21 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
22 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
23 |
|
Lubricant Eye Drops |
|
Phase 4 |
|
|
|
24 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
25 |
|
Blood Substitutes |
|
Phase 4 |
|
|
|
26 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
27 |
|
Plasma Substitutes |
|
Phase 4 |
|
|
|
28 |
|
Dextrans |
|
Phase 4 |
|
|
|
29 |
|
Antiemetics |
|
Phase 4 |
|
|
|
30 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
31 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
32 |
|
Alkylating Agents |
|
Phase 4 |
|
|
|
33 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
34 |
|
Carbonic Anhydrase Inhibitors |
|
Phase 4 |
|
|
|
35 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
36 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
37 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
38 |
|
Brimonidine Tartrate |
|
Phase 4 |
|
70359-46-5 |
|
Synonyms:
AGN-190342LF
AGN-190342-LF
ALPHAGAN
ALPHAGAN P
BRIMONIDINE D-TARTRATE
BRIMONIDINE TARTRATE
|
BRYMONT
LUMIFY
MIRVASO
QOLIANA
UK-1430418
|
|
39 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
40 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
41 |
|
Anesthetics |
|
Phase 4 |
|
|
|
42 |
|
Cefuroxime axetil |
|
Phase 4 |
|
|
3379942 |
Synonyms:
Acetoxyethylcefuroxime
Ceftin
|
Cefuroxime 1-acetoxyethyl ester
Zinnat
|
|
43 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
44 |
|
Ophthalmic Solutions |
|
Phase 4 |
|
|
|
45 |
|
Betaxolol |
Approved, Investigational |
Phase 3 |
|
659-18-7, 63659-18-7 |
2369 |
Synonyms:
1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol
1-(Isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
Alcon brand OF betaxolol hydrochloride
Alcon, betaxolol
Allphar brand OF betaxolol hydrochloride
ALO-140102 FREE BASE
BETAXOLOL
Bétaxolol
Betaxolol alcon
BETAXOLOL HCL
betaxolol HCl|Betoptic®|Kerlone®|SL-75212-10
Betaxolol hydrochloride
Betaxololum
Betoptic
BETOPTIC SUSP
|
Betoptima
Boots brand OF betaxolol hydrochloride
Hydrochloride, betaxolol
KERLEDEX
Kerlon
Kerlone
Lorex brand OF betaxolol hydrochloride
Oxodal
Schwarz brand OF betaxolol hydrochloride
Searle brand OF betaxolol hydrochloride
SL-75212-10
SL-7521210 FREE BASE
Synthelabo brand OF betaxolol hydrochloride
Synthélabo brand OF betaxolol hydrochloride
|
|
46 |
|
Adenosine |
Approved, Investigational |
Phase 3 |
|
58-61-7 |
60961 |
Synonyms:
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-METHYLOL-TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4S,5R)-2-(6-AMINO-9H-PURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-ribofuranose
6-Amino-9-b-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9-β-D-ribofuranosyl-9H-purine
9-b-D-Ribofuranosidoadenine
9-b-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9beta-delta-Ribofuranosyladenine
9-beta-delta-Ribofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9beta-D-Ribofuranosyladenine
9-beta-D-Ribofuranosyladenine
9-Β-D-ribofuranosidoadenine
9-Β-D-ribofuranosyl-9H-purin-6-amine
ADENIN RIBOSIDE
Adenine deoxyribonucleoside
|
Adenine nucleoside
Adenine riboside
Adenine-9beta-delta-ribofuranoside
Adenine-9beta-D-ribofuranoside
Adenocard
Adenocard®|Adenoscan®
Adenocor
ADENOGESIC
Adenoscan
Adenosin
ADENOSINA
ADENOSINE
ADÉNOSINE
ADENOSINUM
Adenyldeoxyriboside
Ade-rib
Ado
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-delta-Adenosine
Boniton
Deoxyadenosine
Desoxyadenosine
Myocol
NSC-7652
Nucleocardyl
Sandesin
SR-96225
Β-D-adenosine
|
|
47 |
|
Papaverine |
Approved, Investigational |
Phase 2, Phase 3 |
|
61-25-6, 58-74-2 |
4680 |
Synonyms:
Cerespan
Chlorhydrate de papaverine
Hydrochloride, papaverine
Mesotina
NSC-136630
Papavarine chlorhydrate
Papaverin
Papaverina
|
PAPAVERINE
Papaverine chlorohydrate
Papaverine hydrochloride
Papaverine monohydrochloride
Papaverinium chloride
Pavabid
Pavatym
|
|
48 |
|
Dipivefrin |
Approved |
Phase 3 |
|
52365-63-6 |
3105 |
Synonyms:
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
(±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
1-(3',4'-Dipivaloyloxyphenyl)-2-methylamino-1-ethanol
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
Adrenaline dipivalate
Alcon brand OF dipivefrin hydrochloride
Allergan brand OF dipivefrin hydrochloride
Apo-dipivefrin
Apotex brand OF dipivefrin hydrochloride
D Epifrin
Diopine
Dipivaloylepinephrine
Dipivalyl epinephrine
Dipivefrin
Dipivefrin acetate, (+-)-isomer
Dipivefrin citrate (1:1), (+-)-isomer
Dipivefrin hydrochloride
Dipivefrin hydrochloride, (+-)-isomer
Dipivefrin monophosphate, (+-)-isomer
Dipivefrin monosulfate, (+-)-isomer
|
Dipivefrin nitrate, (+-)-isomer
Dipivefrin perchlorate
Dipivefrin propanoate, (+-)-isomer
Dipivefrin tartrate (1:1), (+-)-(R-(r*,r*))-isomer
Dipivefrin tartrate (1:1), (R)-(R-(r*,r*))-isomer
Dipivefrin, (R)-isomer
Dipivefrina
Dipivefrine
Dipivéfrine
Dipivefrinum
Dipoquin
DPE
Glaucothil
Glaudrops
Ioquin brand OF dipivefrin hydrochloride
Pharm-allergan brand OF dipivefrin hydrochloride
Pharmascience brand OF dipivefrin hydrochloride
PMS-Dipivefrin
PRO-EPINEPHRINE
Propine
Ratio-dipivefrin
Ratiopharm brand OF dipivefrin hydrochloride
|
|
49 |
|
Memantine |
Approved, Investigational |
Phase 3 |
|
41100-52-1, 19982-08-2 |
4054 |
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
1,3-DIMETHYLAMINOADAMANTANE
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
AKATINOL
Axura
Axura®|Ebixa®|Namenda®
D-145
DMAA
DRG-0267
Ebixa
Exiba
FP-01
Lundbeck brand OF memantine hydrochloride
|
MARIXINO
Memantin
Memantina
Memantina [INN-Spanish]
MEMANTINE
Memantine [INN]
MEMANTINE HCL
Memantine hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
Namenda
NAMENDA XR
NEMDATINE
NSC-102290
SUN-Y7017
VALIOS
|
|
50 |
|
Dopamine |
Approved |
Phase 3 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
Interventional clinical trials:
(show top 50)
(show all 401)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Efficacy and Safety of Latanoprost/Timolol Fixed Combination Dosed Twice Daily Compared to Once Daily in Patients With Primary Open Angle Glaucoma |
Unknown status |
NCT04098861 |
Phase 4 |
Latanoprost/Timolol |
2 |
An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma |
Unknown status |
NCT02792803 |
Phase 4 |
Xalatan;Apo-Latanoprost;Co-Latanoprost |
3 |
Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma |
Unknown status |
NCT01580254 |
Phase 4 |
IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops |
4 |
Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients |
Unknown status |
NCT01446497 |
Phase 4 |
Brimonidine/Timolol mixed combination;Timolol |
5 |
Post Market Multicentric Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle Glaucoma Subjects |
Completed |
NCT02006693 |
Phase 4 |
|
6 |
An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More |
Completed |
NCT01979913 |
Phase 4 |
Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis |
7 |
Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs |
Completed |
NCT00675207 |
Phase 4 |
Brimonidine purite 0.15%;Dorzolamide 2%;Brinzolamide 1% |
8 |
Multicentric Study to Evaluate the Efficacy and Tolerability of an Innovative Formulation of Benzalkonium Chloride-free Latanoprost in Patients With Primary Open-Angle Glaucoma |
Completed |
NCT03331770 |
Phase 4 |
Latanoprost Ophthalmic Product |
9 |
Changes in Peripapillary Blood Flow After Use of Anti-glaucoma Medications: A Prospective, Quantitative OCT Angiography Study |
Completed |
NCT03323164 |
Phase 4 |
Timolol Maleate;Brimonidine Tartrate |
10 |
Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients |
Completed |
NCT03104621 |
Phase 4 |
Benzalkonium chloride (BAK);0.0015% tafluprost |
11 |
Ocular Surface Conditions in Asian Glaucoma Patients With Existing Corneal Disorders Switching From Preserved Prostaglandin Analogues Monotherapy to Preservative-free Tafluprost |
Completed |
NCT04654611 |
Phase 4 |
preservative free tafluprost 0.0015% |
12 |
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance |
Completed |
NCT02017327 |
Phase 4 |
Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose |
13 |
Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension |
Completed |
NCT00372827 |
Phase 4 |
Brinzolamide 1% added to Travoprost 0.004% |
14 |
24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients |
Completed |
NCT00330577 |
Phase 4 |
timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears) |
15 |
A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension |
Completed |
NCT00300079 |
Phase 4 |
brinzolamide 1.0% |
16 |
Health-Related Quality of Life in Two Pathways for Newly Diagnosed Open Angle Glaucoma and Ocular Hypertension: an Unmasked, Multi-centre, Randomised Controlled Trial of Initial Selective Laser Trabeculoplasty Versus Medical Therapy |
Completed |
NCT03395535 |
Phase 4 |
Primary Medical Treatment Pathway |
17 |
A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent |
Completed |
NCT01252914 |
Phase 4 |
|
18 |
A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents |
Completed |
NCT01252888 |
Phase 4 |
|
19 |
A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents |
Completed |
NCT01252862 |
Phase 4 |
|
20 |
Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions |
Completed |
NCT01162603 |
Phase 4 |
TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS |
21 |
Phase 4 Study to Evaluate Efficacy And Safety of Pneumatic Trabeculoplasty (PNT) in Subjects Affected by Primary Open Angle Glaucoma |
Completed |
NCT01540331 |
Phase 4 |
|
22 |
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension |
Completed |
NCT00759239 |
Phase 4 |
Travoprost 0.004% / Timolol maleate 0.5% |
23 |
A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension |
Completed |
NCT00527592 |
Phase 4 |
Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®) |
24 |
A Crossover, Double-Masked Comparison Investigating the 24-Hour Intraocular Pressure Control With the Travoprost/Timolol Fixed Combination Versus Travoprost, When Both Are Given in the Evening, in Subjects With Primary Open-Angle Glaucoma |
Completed |
NCT00444184 |
Phase 4 |
Travoprost/timolol fixed combination, travoprost |
25 |
Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma |
Completed |
NCT01978015 |
Phase 4 |
travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose |
26 |
Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension |
Completed |
NCT02796560 |
Phase 4 |
Brand name travoprost;Generic travoprost |
27 |
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension |
Completed |
NCT02061683 |
Phase 4 |
Bimatoprost 0.03% |
28 |
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension |
Completed |
NCT02020512 |
Phase 4 |
0.03% Bimatoprost |
29 |
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension |
Completed |
NCT02003534 |
Phase 4 |
0.15% Brimonidine Tartrate |
30 |
Quality of 24-hour Intraocular Pressure Control Obtained With Dorzolamide/Timolol Fixed Combination (DTFC) Compared With the Brimonidine/Timolol Fixed Combination (BTFC) in Subjects With Primary Open-angle Glaucoma |
Completed |
NCT00972257 |
Phase 4 |
treatment with dorzolamide/timolol;treatment with brimonidine/timolol |
31 |
A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma |
Completed |
NCT00911924 |
Phase 4 |
|
32 |
An Open, Non-randomized Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma on Tear Film Thickness |
Completed |
NCT03204487 |
Phase 4 |
Tafluprost 15µg/ml |
33 |
Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension. |
Completed |
NCT00941096 |
Phase 4 |
Bimatoprost and Bimatoprost/Timolol fixed combination. |
34 |
A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension |
Completed |
NCT00140062 |
Phase 4 |
latanoprost 0.005% (Xalatan) |
35 |
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) |
Completed |
NCT01594970 |
Phase 4 |
Bimatoprost 0.01% |
36 |
A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma |
Completed |
NCT00913029 |
Phase 4 |
latanoprost/timolol |
37 |
The Efficacy and Safety of Travoprost, 0.004% Versus Tafluprost, 0.0015% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients |
Completed |
NCT00966940 |
Phase 4 |
Travoprost 0.004% ophthalmic solution (TRAVATAN);Tafluprost 0.0015% ophthalmic solution |
38 |
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma |
Completed |
NCT03966560 |
Phase 4 |
Brimonidine Tartrate;Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops;Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension;Travoprost and Timolol;Bimatoprost and Timolol;Latanoprost |
39 |
A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) |
Completed |
NCT02863705 |
Phase 4 |
brimonidine tartrate/timolol malate Ophthalmic Solution;bimatoprost ophthalmic solution 0.01% |
40 |
The Effect of Topical Brimonidine on the Hemodynamics of the Optic Nerve Head and Retinochoroidal Circulation in Patients of Primary Open Angle Glaucoma Using Optical Coherence Tomography Angiography |
Completed |
NCT05474716 |
Phase 4 |
Brimonidine tartrate 0.2% ophthalmic solution |
41 |
A Study of LUMIGAN® RC in the Clinical Setting |
Completed |
NCT01833741 |
Phase 4 |
Bimatoprost 0.01% |
42 |
Randomized, Controlled Treatment With an Intracanalicular Dexamethasone (0.4mg) Insert Following Cataract Surgery With IOL Combined With MIGS, Specifically iStent, iStent Inject or KDB in Patients With POAG or Ocular Hypertension (OHTN) |
Completed |
NCT04465864 |
Phase 4 |
Intracanalicular Dexamethasone, 0.4 mg insert |
43 |
Investigation of the Effect of Travoprost Ophthalmic Solution of Lowering Intraocular Pressure in Patients With Normal Tension Glaucoma |
Completed |
NCT01995136 |
Phase 4 |
Travoprost Ophthalmic Solution 0.004% |
44 |
A 6-week, Double Masked, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Twice-daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to Travoprost 0.004% in Reducing Intraocular Pressure in Patients With Normal Tension Glaucoma |
Completed |
NCT03150160 |
Phase 4 |
brinzolamide 1%/brimonidine 0.2% fixed combination;Placebo;travoprost 0.004% ophthalmic solution |
45 |
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom (Fixed Combination Of Latanoprost And Timolol) In Patients With Poag Or Oh. A 6-Month, Open, Multi-Center Trial In Italy |
Completed |
NCT00143208 |
Phase 4 |
Xalacom |
46 |
Safety and Efficacy Study in NTG, POAG, Glaucoma Suspect, Ocular Hypertension Patients With Diagnosed Prostaglandin Associated Peri-orbitopathy Switching From Preserved Prostaglandin Analogues Monotherapy to Omidenepag Isopropyl |
Recruiting |
NCT05279716 |
Phase 4 |
Eybelis ophthalmic solution 0.002% |
47 |
Phase IV Clinical Study to Compare the Efficacy of the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination to the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination, in Primary Open Angle Glaucoma or Ocular Hypertension Patients. |
Recruiting |
NCT04702789 |
Phase 4 |
Dorzolamide-timolol-brimonidine and latanoprost;Dorzolamide-timolol and latanoprost |
48 |
Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos. |
Recruiting |
NCT05606796 |
Phase 4 |
Latanoprost 0.005% Ophthalmic Solution |
49 |
A Prospective Randomized Clinical Trial Comparing Three Delivery Methods of Mitomycin-C for Trabeculectomy Surgery: Preoperative Subconjunctival Injection, Intraoperative Subconjunctival Injection, and Topical Application (Conventional Use) During Trabeculectomy Surgery |
Recruiting |
NCT03875911 |
Phase 4 |
Mitomycin C |
50 |
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1% |
Not yet recruiting |
NCT04007276 |
Phase 4 |
brimonidine tartrate ophthalmic solution 0.025% |
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Glaucoma, Primary Open Angle:
Embryonic/Adult Cultured Cells Related to Glaucoma, Primary Open Angle:
|